Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | DCC-3014 |
Synonyms | |
Therapy Description |
DCC-3014 inhibits CSF1R, potentially resulting in increased anti-tumor immune response in combination with other agents (Cancer Res 2016;76(14 Suppl):Abstract nr 4889). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCC-3014 | DCC3014|DCC 3014 | CSF1R Inhibitor 25 | DCC-3014 inhibits CSF1R, potentially resulting in increased anti-tumor immune response in combination with other agents (Cancer Res 2016;76(14 Suppl):Abstract nr 4889, PMID: 29679908). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03069469 | Phase I | DCC-3014 | Study of DCC-3014 in Patients With Advanced Malignancies | Recruiting | USA | CAN | 5 |